Nimbus Organized Annual ADME Meeting
News Nov 22, 2005
"Discover the hidden properties!" was the slogan of the annual ADME meeting organized by Nimbus Biotechnology.
During this outstanding meeting scientists presented and discussed current strategies for ADME issues.
Dr. Keldenich (Bayer HealthCare AG, Germany) reported in his presentation about a correlation of membrane affinity measured by the well known TRANSIL® technology to the permeability determinate by double sink PAMPA for a subset of compounds.
He also pointed out that the TRANSIL® technology has additionally advantages like reliability and easiness of the assays for membrane affinity.
In this respect Dr. Schmitt (Bayer Technology Services, Germany) said in his presentation that the membrane affinity hide much additional information about a compound.
To discover those properties it is necessary to use this physicochemical data as an input parameter of physiology based pharmacokinetic modelling, so that the user is able to predict important ADME parameters like fraction absorbed, fraction unbound, volume of distribution or plasma/organ partitioning coefficients.
Wolfgang Lerch, CEO of NIMBUS Biotechnology, stated that, "The membrane affinity is a reliable, fast and easy to measure parameter which hide important information like a gold mine."
"During the meeting it was impressively demonstrated by several speakers that TRANSIL® ADME assays are extremely valuable for drug discovery."
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE